Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study Evaluating the Safety, Pharmacology, and Preliminary Activity of VT1021 in Patients With Advanced Solid Tumors

NCT03364400 is registered in ClinicalTrials.gov with Vigeo Therapeutics, Inc. as lead sponsor.

NCT NCT03364400
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03364400 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study Evaluating the Safety, Pharmacology, and Preliminary Activity of VT1021 in Patients With Advanced Solid Tumors
Lead sponsor
Vigeo Therapeutics, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
November 28, 2017
Completion date
June 30, 2024
Enrollment
116 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor